A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 10 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the medication Clobetasol, specifically in foam form (ATC D07AD01). This agreement is part of a framework established under § 130a Abs. 8 SGB V, which allows health insurance companies and pharmaceutical fir
IKK classic is announcing that it will enter into non-exclusive discount agreements with interested and qualified pharmaceutical companies for various active ingredients and combinations of active ingredients. These agreements will be based on fixed, non-negotiable terms in accordance with § 130a Ab
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Abiraterone, specifically in the 500mg strength and 90 tablet pack size. Under § 130a Abs. 8 SGB V, health insurance funds and pharmaceutical companies can enter into framework di
The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process will provide uniform contract conditions and access procedu
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Rivaroxaban (ATC: B01AF01 - in all strengths except 2.5 mg per divided oral dosage form) under an 'open-house model'. All eligible and interested ph
This contract opportunity involves establishing non-exclusive discount agreements for the medication Certolizumab pegol, as per § 130a Abs. 8 SGB V. The agreements will be made under an Open-House model, allowing all interested pharmaceutical companies to participate during the application period, p
This contract opportunity involves establishing non-exclusive discount agreements for pharmaceuticals containing the active ingredients Brinzolamid and Brimonidin (official ATC code: S01EC24) under the German Social Code. The agreements will be made through an Open-House model, allowing all interest
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Rivaroxaban, specifically for film-coated tablets excluding the 2.5 mg strength. The contracts will be in effect from October 1, 2025, to September 30, 2027, with the option for suppliers to e
The German health insurance companies and pharmaceutical companies can enter into framework discount agreements for medications covered by statutory health insurance, as permitted by § 130a paragraph 8 of the Social Code Book V. The DAK-Gesundheit will conduct a formal procurement process for the ac
This is not a standard procurement process but an open-house model for pharmaceutical companies. The AOK Bayern intends to establish non-exclusive discount agreements for the drug Leuprorelin (ATC L02AE02) with all interested pharmaceutical companies that meet the specified eligibility criteria. The
